Skip to main content
Equibles
PHGE logo

PHGE · BiomX Inc.

Track PHGE — free

Use PHGE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.14 0.00 (-1.27%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 19, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company's ability to continue as a going concern depends on its ability to obtain additional financing or to generate sufficient operating cash flows from its newly acquired subsidiaries, neither of which can be assured. These factors raise substantial doubt about the Company's ability to continue as a going concern. The condensed consolidated interim financial statements have been prepared on a going concern basis and do not include any adjustments that may result from the outcome of these uncertainties.”
View the 10-Q filed Aug 19, 2026
Market Cap
$3.80M
Shares
26.72M

PHGE metrics

49 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.14
Market cap
$3.80M

Price action

19 metrics
Price change (1W)
+8.8%
Price change (30D)
-22.1%
Price change (3M)
-83.6%
Price change (6M)
-97.7%
Price change (YTD)
-92.4%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
225.8%
Beta
1.6
RSI (14D)
33.8
Price vs SMA 50
-31.4%
Price vs SMA 200
—
Avg volume (3M)
2.87M
Relative volume
1.2
Average dollar volume
$797,487

Company

3 metrics
Sector
Industrials
Industry
Aerospace & Defense
Shares outstanding
26.72M

Valuation

12 metrics
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 14,042.1%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.4
reciprocal yield 284.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,190.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-12

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$32.99M
Net income (TTM)
−$45.49M
Trailing 12 months
Diluted EPS (TTM)
$20.01
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$3,523.84

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
-89.9%
Shares change YoY
+525.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
-50.3%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-418.7%
Return on assets
-161.4%
Debt / equity
0.0
Current ratio
0.2
EBITDA (TTM)
−$32.02M
Free cash flow (TTM)
—
Quick ratio
0.2
Interest coverage
-148.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$115,000
Latest balance sheet
Cash & equivalents
$347,000
Total assets
$28.19M
Total debt
$457,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$18.15M
Capital expenditures (TTM)
—
R&D (TTM)
$21.29M
SG&A (TTM)
—
Stock compensation (TTM)
$2.79M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
9
13F filer change QoQ
-4
Institutional ownership
2.6%

Short interest

3 metrics
Short interest
1.3%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
28 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1739174 CUSIP 09090D509 13F (30d) 9 filings 8 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)